The .bed file contains the coverage of genes, intronic regions, MSI, and SNPs in the Twist CGP panel. 

Early and accurate cancer detection can change lives — and the future of # oncology. Join us for this webinar on demand with Dr. Smiths S. Lueong (Priv.-Doz. Dr. rer. nat.), Senior Scientist at University Hospital Essen and expert in molecular oncology, as he explores how cfDNA methylation patterns are transforming multi-cancer early detection through liquid biopsy innovations. Don’t miss this opportunity to discover the latest breakthroughs in epigenetic biomarkers, NGS-based profiling, and clinical translation that are reshaping how we detect and treat cancer.

Founded in 2012, OncoDNA set out to improve outcomes for patients with late-stage disease. By combining its deep subject matter expertise with advanced molecular tools, the OncoDNA team generates a detailed report for oncologists that describes each patient’s tumor. Over the past decade, OncoDNA has refined its approach, optimizing for scale, accuracy, and information density. One such refinement included the adoption of targeted sequencing with Twist reagents. We recently spoke with Koenraad Eycken, Chief Product Officer at OncoDNA, to learn more about the company’s evolution and how their collaboration with Twist is helping hospitals around the world.